scenarios in which all cell types are unidirectionally differentially methylated to a similar degree (Fig. 1c) . CellDMC can also handle more complex scenarios in which a DMC occurs in two cell types with opposite directionality (hypomethylated in one and hypermethylated in the other) (Fig. 1d) , and which may not be identifiable by current state-of-the-art DMC calling algorithms.
To estimate cell-type fractions, CellDMC applies our previously validated EpiDISH algorithm 16 in an iterative hierarchical procedure called HEpiDISH 17 , which leads to improved cell type-fraction estimates in complex tissues by recognizing that cell types are naturally arranged along a developmental tree (Methods and Supplementary Data 1). In the context of epithelial tissues, HEpiDISH accomplishes this by using two distinct DNAm reference matrices, a primary reference matrix for the estimation of total epithelial, total fibroblast and total immune cell fractions, and a separate, secondary, nonoverlapping DNAm reference for the estimation of underlying immune cell-subtype fractions 17 . In total, HEpiDISH can estimate cell-type fractions for nine to ten different cell types commonly found in epithelial tissues, including epithelial cells, fibroblasts and seven major types of immune cells (Methods) 17 . For tissues such as breast, which contain a relatively large fraction of adipocytes 18 , the primary reference also includes a representative DNAm profile for fat cells 17 .
Validation of CellDMC on in silico mixtures.
To test CellDMC's ability to detect DMCTs, we first considered a number of different simulation scenarios in which we mixed together real DNAm profiles representing epithelial, fibroblast and immune cell types in known mixing proportions, introducing DMCs in one, two or all cell types, with parallel or opposite directionality, and over a range of different signal-to-noise ratios (SNRs) (Methods and Supplementary Table 1 ). Our choice of SNRs is conservative, corresponding to differences in average DNAm within an affected cell type of approximately 0.4-0.5 (40-50%) in the high-SNR regime (SNR ~3) down to changes as small as 0. An outstanding challenge of epigenome-wide association studies (EWASs) performed in complex tissues is the identification of the specific cell type(s) responsible for the observed differential DNA methylation. Here we present a statistical algorithm called CellDMC (https://github.com/sjczheng/EpiDISH), which can identify differentially methylated positions and the specific cell type(s) driving the differential methylation. We validated CellDMC on in silico mixtures of DNA methylation data generated with different technologies, as well as on real mixtures from epigenome-wide association and cancer epigenome studies. CellDMC achieved over 90% sensitivity and specificity in scenarios where current state-of-the-art methods did not identify differential methylation. By applying CellDMC to an EWAS performed in buccal swabs, we identified smoking-associated differentially methylated positions occurring in the epithelial compartment, which we validated in smoking-related lung cancer. CellDMC may be useful in the identification of causal DNA-methylation alterations in disease.
low-SNR regime (SNR < 1) ( Supplementary Fig. 2 ). In effect, the low-SNR regime corresponds to a scenario in which only 10% of single cells of a given type exhibit a common DNAm change. Considering first scenarios in which the underlying cell-type fractions do not change appreciably between cases and controls, CellDMC detected DMCTs with high sensitivity and specificity (Fig. 2a) . For instance, even when SNR < 1, CellDMC obtained a sensitivity > 0.75 for all scenarios in which differential methylation is unidirectional, regardless of the number of affected cell types (Fig. 2a ). For scenarios with bidirectional changes, CellDMC could detect DMCTs with a sensitivity > 0.75 as long as the SNR was ~1.8 or above (Fig. 2a) . In line with these high sensitivity values, we observed excellent agreement between the predicted DNAm difference in the underlying DMCTs and the true DNAm difference, irrespective of SNR and whether DNAm alterations were uni-or bidirectional (Fig. 2b) . Importantly, CellDMC allows DMCTs to be ranked in each cell type according to their statistical significance with the ranking highly correlated with true effect size, as required ( Supplementary Fig. 2 ). All of the above results were largely unchanged when cell-type fractions were allowed to vary between cases and controls ( Supplementary Fig. 3 ), or when DMCs occurred in only one of the underlying immune cell subtypes (compared to the previous case in which the DMCs were common to all immune cells) ( Supplementary Figs. 4-6 ). CellDMC also attained high sensitivity and specificity when in silico mixtures were generated purely from immune cell subtypes (without admixture by epithelial and fibroblast cells), representing the more common scenario of EWASs performed in whole or peripheral blood ( Supplementary Fig. 6 ). estimates were perturbed using either theoretical or empirical confidence intervals (Supplementary Data 4 and 5).
We also assessed CellDMC's power and specificity to detect DMCTs as a function of sample size, cell-type complexity and missing cell types. At a sample size of 100 controls and 100 cases, the power of CellDMC was always > 0.75 when the SNR was > 1.8 (corresponding to DNAm changes > 0.2 in individual cell types) ( Fig. 2c and Supplementary Fig. 7) . Notably, as long as the fraction of the affected cell type was distributed uniformly across samples (thus exhibiting a fairly large range), CellDMC's sensitivity was robust to cell-type complexity, that is, the number K of cell types in the mixture, although due to limitations on data availability, we could only assess this up to a value of K = 7 ( Supplementary Fig. 8 ). We also assessed performance as a function of the variance of the altered cell-type fraction, estimating that sensitivity of CellDMC would remain > 50% as long as the range of fractions exhibited by the affected cell type was > 0.2 ( Fig. 2d and Supplementary Fig.  8 ). CellDMC was also robust when one major unaffected cell type was missing from the reference DNAm matrix, whereas reduction in sensitivity was relatively marginal when an altered cell type was missing from the reference (Supplementary Fig. 9 ). In the case of blood tissue we simulated a realistic scenario in which cell-type fractions were modeled as observed in real blood EWASs but with one cell type (CD8 + T cells) missing from our reference; sensitivities for detection of DMCTs in CD4 + T cells were reduced at most by only 15% (Supplementary Fig. 9 ). Thus, these data support the view that CellDMC can reliably detect DMCTs in a wide range of different realistic scenarios. However, we also expect CellDMC's power to be strongly influenced by cell-type complexity, in line with the fact that DNAm references become less reliable as K increases, and also because specific cell-type proportions may exhibit small variation or fall below detection levels.
CellDMC outperforms state-of-the-art DMC calling methods. CellDMC outperformed state-of-the-art reference-based and reference-free DMC calling methods, particularly when DNAm changes were bidirectional ( Fig. 3 and Supplementary Figs. 10  and 11 ). For instance, when DNAm changes occurred in two of the underlying cell types with opposite directionality (denoted Bi-2C), conventional reference-based DMC calling that only included the estimated cell-type fractions as covariates 7 did not resolve the underlying DMCs, resulting in sensitivities well below 0.25 ( Fig. 3 and Supplementary Fig. 10 ). In contrast, CellDMC attained sensitivities that ranged from > 0.95 for high SNRs to ~0.5 for low SNRs. When bidirectional changes occurred in more than two cell types (denoted Bi-AllC), CellDMC also attained significantly higher sensitivity values than conventional noninteractionbased DMC calling ( Fig. 3 and Supplementary Fig. 10 ). Similar improvements in sensitivity of CellDMC over state-of-the-art reference-free methods (SVA and RefFreeEWAS) 8, 19, 20 were also observed ( Fig. 3 and Supplementary Fig. 11 ). In line with the sensitivity results, CellDMC's specificity was also higher and more stable than that of competing methods (Fig. 3) . Thus, these data demonstrate that CellDMC can attain sensitivity and specificity values ~100% in scenarios in which current state-of-the-art methods would fail to detect DMCs.
Validation of CellDMC on bisulfite sequencing data. All previous simulation models mixed together DNAm profiles generated with Illumina 450k/EPIC technology 21, 22 , a platform matched to the one used to generate the DNAm references. Thus, to demonstrate the applicability of CellDMC to samples generated with a different technology, we devised in silico mixture simulation models using whole-genome bisulfite sequencing (WGBS) profiles of purified cell types, generated as part of the International Human Epigenome Consortium (IHEC) 23 (Supplementary Data 6). Although CellDMC's performance measures dropped upon application to WGBS data, the reduction was only relatively marginal, with sensitivity and specificity values remaining high (sensitivity and specificity were still > 90% for the higher SNR values, Supplementary Fig. 12 ). Thus, we conclude that profiling technology is not a major limiting factor for CellDMC. Validation of CellDMC in a blood EWAS. Next, we tested the ability of CellDMC to detect known DMCTs in a real EWAS. A recent EWAS for rheumatoid arthritis conducted on purified B cells identified a total of ten DMCs, which were validated in two independent EWAS cohorts that were also profiled for purified B cells 24 . Thus, we reasoned that application of CellDMC to an independent rheumatoid arthritis EWAS performed on 689 blood samples 5 should be able to identify these ten rheumatoid arthritis DMCs as being differentially methylated specifically in B cells. CellDMC predicted eight of these ten to be differentially methylated, and seven of the ten to be B-cell DMCTs (false discovery rate (FDR) < 0.05, Fig. 4a ). Notably, CellDMC predicted the DNAm difference between rheumatoid arthritis cases and controls to occur primarily in B cells, and not in the other immune cell subtypes ( Fig. 4a) , despite the fact that on average B cells accounted for only 2% of blood cell subtypes in the samples, and exhibited relatively little variation (Fig. 4a) . Although the median absolute difference in B-cell fractions between the 689 samples was only 1.5%, five samples exhibited fractions > 10%, and therefore the ability of CellDMC to detect validated B-cell DMCTs is consistent with our previous simulation result (Fig. 2d) . Importantly, we estimated the chance that CellDMC would call seven of ten randomly selected CpGs to be B-cell DMCTs at their observed significance levels to be < 0.00001 (Fig. 4a) . We verified that results were not affected by the choice of cell type-fraction estimation algorithm, or by removal of one of the other minor blood cell subtypes from the DNAm reference matrix ( Supplementary Fig. 13 ). Notably, had we applied a standard noninteraction-based reference model 5 ). Bar to left indicates ten CpG sites that have been validated to be rheumatoid arthritis (RA)-associated DMCs in 3 independent purified B-cell cohorts, with their directionality of DNAm change as indicated 24 . The central heatmap displays the predicted DMCTs from CellDMC, based on a two-tailed t-test for the interaction term. Statistical significance of this result was assessed using 100,000 Monte-Carlo runs, where in each run ten CpGs were selected at random and their weighted averaged t-statistic (t-stat., gray curve and area) was compared to the observed value (vertical red line). Boxplots display cell-type fraction estimates across the 689 samples. Boxes indicate 25th and 75th percentiles. Whiskers extend to the largest values no further than 1.5 IQR from these percentiles. B, B cells; CD4T, CD4 + T cells; CD8T, CD8 + T cells, Gran, granulocytes; Mono, monocytes. b, Validation of CellDMC's detection of true breast cancer epithelial DMCs. Scatterplot of DNAm difference between breast cancer cell lines and normal mammary epithelial cell lines (y-axis) against the predicted DNAm difference from CellDMC between the epithelial component of breast cancer tissue (n = 305 samples) and that of normal breast (n = 92), for a total of ~19,000 true-positive breast cancer epithelial DMCs. One-tailed Fisher-test P value is given. HypoM, hypomethylated; HyperM, hypermethylated; Incons, inconsistent. c, Validation of CellDMC in endometrial TCGA cancer study. Scatterplots of β (adjusted for cell-type fractions) of one of the HAND2 CpGs against fractions of epithelial (fEpi), fibroblast (fFib) and total immune cells (fIC), with samples labeled according to endometrial cancer (red) or normal endometrium (blue). d, CellDMC predictions for DNAm differences between cancer and normal in each of the three cell types, for all CpGs mapping to HAND2.
to identify DMCs, six of the ten validated rheumatoid arthritis DMCTs would have been detected as DMCs using the same FDR < 0.05 threshold but without knowledge of the underlying DMCT being B cells. We also note that CellDMC led to a more than four-fold reduction of DMCs compared to a method that did not adjust for cell-type fractions, and a more than two-fold reduction of DMCs compared to a noninteraction-based model, with relatively little overlap between DMCs called by CellDMC and the standard noninteraction model (Supplementary Table 2 ). Thus, like the standard noninteraction-based model, CellDMC can remove many associations caused by changes in the granulocyte/lymphocyte ratio 5 , while also identifying different DMCs than those found using the standard model.
Validation of CellDMC in cancer epigenome studies.
To demonstrate the ability of CellDMC to detect DMCTs in solid epithelial tissues, we applied it to the breast cancer EWAS setting, for which we had previously constructed a gold-standard set of 19,379 true positive breast cancer epithelial DMCs 9, 17 . This set was obtained by intersecting DMCs from a comparison of breast cancer epithelial to normal mammary epithelial cell lines (thus representing relatively pure epithelial cell populations) with a corresponding list of DMCs derived from The Cancer Genome Atlas (TCGA) breast cancer study 25 . We reasoned that applying CellDMC on our independent breast cancer tissue EWAS 18 should not only validate the breast cancer epithelial DMCs but also predict the epithelial compartment to be the main DMCT. Confirming this, mean methylation differences between the epithelial cells in breast cancer and those in normal tissue as predicted by CellDMC showed excellent correlation with the DNAm differences observed in the actual cell lines (Fig. 4b) . Overall, the magnitude of DNAm changes was still larger in the cell lines, possibly owing to cell-culture effects or cg03636183  cg05575921  cg19859270  cg21161138  cg05951221  cg01940273  cg06126421  cg21566642  cg02657160  cg03329539  cg06644428  cg14817490  cg25648203  cg26703534  cg03991871  cg09935388  cg19572487  cg23576855  cg24859433  cg25189904  cg01731783  cg01899089  cg04885881  cg07123182  cg08709672  cg11314684  cg11660018  cg12803068  cg12806681  cg12876356  cg15342087  cg20295214  cg21611682  cg22132788  cg27241845  cg00310412  cg01692968  cg01901332  cg02451831  cg03547355  cg05284742  cg06060868  cg11207515  cg11231349  cg12075928  cg13193840  cg13976502  cg14580211  cg14753356  cg18316974  cg21121843  cg21913886  cg22851561  cg23079012  cg23161492  cg23771366  cg23916896  cg24090911  cg24996979  cg25949550  cg26271591 the cells' longer proliferative history (Fig. 4b) . CellDMC detected DMCs with ~75% sensitivity and 70% specificity, and detected the DMCTs as occurring in the epithelial compartment with > 60% sensitivity ( Supplementary Fig. 14) . Although it is unknown whether the 19,379 true positive breast cancer epithelial DMCs are also altered in fibroblasts, fat and immune cells, CellDMC predicted much smaller fractions of these loci to be altered in fat and immune cells (Supplementary Fig. 14) . As a third validation using real data, we considered the case of the HAND2 gene in endometrial cancer 26, 27 . We had previously discovered and validated hypermethylated DMCs in endometrial cancer that map to the first exon region of the HAND2 gene, which is a main target of the progesterone-receptor tumor suppressor pathway 26, 27 . HAND2 is expressed in normal endometrial tissue including stromal fibroblasts, but lacks expression in endometrial cancer and the stromal fibroblasts of cancer tissue 26 , suggesting that the observed hypermethylation occurs in both epithelial and fibroblast cells. Indeed, the relatively large difference in DNAm (Δ β ~0.5) observed between endometrial cancer and normal endometrial tissue 26 is a strong indication that the unidirectional DNAm change occurs in both epithelial and fibroblast compartments. Application of CellDMC to the TCGA endometrial cancer study 28 confirmed that the DNAm change occurs in the epithelial and fibroblast cells of the tissue (Fig. 4c,d) , and that the alteration in fibroblasts is local to the first exon region (Fig. 4d and Supplementary Data 7) . Notably, CellDMC also predicted the immune-cell compartment to be differentially methylated, albeit less strongly so (Fig. 4c,d ). This is also consistent with the observation that these HAND2 CpG sites become hypermethylated with age in blood 29 , and that the unmatched TCGA endometrial cancers were derived from older women. Thus, the prediction of CellDMC that these specific HAND2 CpGs define DMCs in all three major cell types within the endometrial tissue is entirely consistent with previous knowledge and data.
CellDMC identifies smoking-associated DNAm changes in epithelial cells. Finally, to demonstrate how CellDMC may help provide new biological insight, we applied the method to the largest EWAS cohort of buccal swab samples 30 , consisting of 790 samples from women all aged 53 but with a wide range of different lifetime levels of smoking exposure. As we expected, buccal swabs contained mainly epithelial and immune cells (Supplementary Data 8) , and thus we used CellDMC to predict smoking-associated DMCTs in these two cell types. By comparison to a gold-standard list of 62 true smoking-associated DMCs, which have been validated in at least three independent whole-blood EWASs 31 , we confirmed CellDMC's sensitivity for detecting true DMCTs: most of the gold-standard DMCs were predicted to be hypomethylated specifically in the immune cell compartment of the buccal tissue (Fig. 5a ), in line with their observed hypomethylation in blood EWASs
31
. Confirming CellDMC's specificity, the top-ranked DMCTs in immune cells have all been previously validated as smoking-associated DMCs in blood (Fig. 5a ). Although most of the 62 gold-standard smoking DMCs in blood were not predicted to be altered in the epithelial cells of the buccal swabs, the great majority (> 90%) of DMCTs were predicted to occur in the epithelial compartment, skewed strongly toward hypermethylation ( Supplementary Fig. 15 ). To validate these epithelial DMCTs, we posited that their variance in DNAm levels would increase with the fraction of epithelial cells in lung squamous cell carcinoma 32 , a cancer strongly associated with smoking, while also exhibiting a concomitant decrease in variance in samples with a higher immune cell content. We confirmed this pattern for the topranked hypomethylated epithelial DMCT (Fig. 5b) and for most of the other epithelial DMCTs with high statistical significance ( Fig. 5c and Methods). Moreover, predicted hyper-and hypomethylated epithelial DMCTs exhibited a highly significant trend toward positive and negative correlations, respectively, between their DNAm levels and the estimated epithelial cell-type fractions, as required for consistency (Fig. 5d) . To confirm the biological and clinical importance of these findings, we posited that the DNAm alterations in the epithelial cells would exhibit increased deviations in lung cancer compared to the normal adjacent tissue, owing to an increase in the epithelial fraction in the tumors (Fig. 5e ). Confirming our expectation, hypermethylated and hypomethylated epithelial DMCTs exhibited increased and decreased levels of DNAm in lung cancer, respectively (Fig. 5f) . Consistent with the total immune cell fraction not being altered between normal and cancer cells, the topranked DMCTs specifically hypomethylated in immune cells did not exhibit decreased levels in cancer, but increased levels, probably due to shifts in the specific immune cell-subtype proportions (Fig.  5f) . Thus, the epithelial smoking DMCTs identified here represent epigenetic alterations occurring in the squamous cell of origin of smoking-related lung cancer and therefore may mark cells that are selected for during lung carcinogenesis.
discussion
CellDMC identified validated DMCTs in a minor cell subpopulation (B cells) in the context of a large whole-blood EWAS for rheumatoid arthritis. The application of CellDMC to a smoking EWAS performed in buccal swabs suggests that many of the topranked smoking-associated CpGs detected in these buccal swabs are the result of DNAm changes in the infiltrating immune cells, but that many other DMCs also occur specifically in the epithelial compartment. These alterations and not those seen in the immune cells become aggravated in lung cancer. These specific DNAm changes in the lung epithelium may affect or reflect deregulation of transcription factor regulatory networks that contribute causally to lung cancer development in addition to those that occur in immune cells 33 . Thus, we expect that widespread application of CellDMC to existing and future EWASs will help elucidate the role of DNAm changes and cell types in disease without the need to use fluorescence-activated cell sorting or purify samples. In this regard, the main limitations of our method are only extrinsic factors such as the need for a large sample size and the availability of DNAm reference profiles for the main cell types in the tissue of interest.
The ability of CellDMC to rank CpGs according to their probability of being differentially methylated in each of the underlying cell types will be invaluable for EWASs and cancer epigenome studies. It could help improve biological interpretation, prioritize candidates that require functional validation, and elucidate causal pathways to disease.
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Methods

Estimation of cell-type fractions in complex tissues using EpiDISH and
HEpiDISH. Estimation of the fractions of cell types in a given sample constitutes the first step of the CellDMC algorithm and uses our previously validated EpiDISH 16 and HEpiDISH 17 methods. We use these methods to estimate celltype fractions for in silico generated mixtures as well as for real samples from EWAS and cancer epigenome studies. Which method we use-EpiDISH or a hierarchical iterative version of it called HEpiDISH-depends on the desired celltype resolution, as we explain next.
In the case of whole blood, peripheral blood or in silico mixtures of blood cell subtypes, we use the EpiDISH procedure with a DNAm reference matrix defined over 333 immune cell subtype-specific DMCs and seven immune cell subtypes 16 . Briefly, EpiDISH models the DNAm profile of any given sample as a linear mixture of the DNAm profiles for the individual cell types making up the sample. The associated multivariate linear regression is run using only the 333 immune cell subtype-specific DMCs, and is performed using a robust M-estimator, as implemented in the rlm function of the MASS R package 34 . We refer to this implementation as robust partial correlations (RPCs) 16 . In this framework, the nonnegativity and normalization constraints on the cell-type fractions (the estimated regression coefficients) are imposed a posteriori; that is, negative weights are set to zero and all other nonzero weights are normalized so that their sum is 1. As we have shown earlier 16 , the RPC method improves inference, albeit marginally so, over the alternative approach, which is to impose these constraints during inference via quadratic programming or constrained projection optimization 7 . RPC also performs similarly to another nonconstrained approach that uses a penalized support vector regression model called CIBERSORT 16, 35 . In this work we use EpiDISH with RPC throughout and only use constrained projection for comparative purposes.
In the case of solid epithelial tissues and in silico mixtures of epithelial, fibroblast and various immune cell subtypes, and when we need only to estimate cell-type fractions for the total epithelial, total fibroblast and total immune cell fractions, we once again use EpiDISH with RPC, but now with a DNAm reference matrix defined over 716 DMCs and three cell types (generic epithelial, generic fibroblast and a generic immune cell, denoted as the EpiFibIC reference matrix), as we derived and validated previously in Zheng et al. 17 . The 716 DMCs are highly discriminative of the three main cell types, exhibiting large differences in mean DNAm among epithelial, fibroblast and immune cells 17 . In some of the simulation scenarios, we also estimate fractions for individual immune cell subtypes, in which case we use our validated HEpiDISH algorithm 17 . As explained in Zheng et al. 17 , HEpiDISH works by implementing EpiDISH in an iterative hierarchical fashion, first estimating total epithelial, total fibroblast and total immune cell fractions using the EpiFibIC reference, and then estimating proportions for the seven individual immune cell subtypes using a 188-DMC subset of the original 333-DMC reference used to estimate fractions in blood. A key point is that the 188 DMCs do not share any overlap with the 716 DMCs of the EpiFibIC reference, and that all 188 DMCs have been selected to ensure that their median DNAm levels do not vary appreciably (most differences are < 0.05 and the maximum difference is 0.3, in absolute terms) between the epithelial, fibroblast and immune cells. This latter criterion helps ensure that the error or noise induced by inferring immune cell-subtype fractions in the mixture using a reference matrix that does not include epithelial and fibroblast references is less than the effect size or signal of the 188 DMCs (because any of the original 333 DMCs in the blood reference exhibit big differences in DNAm, that is, at least ± 0.5 with the great majority exhibiting differences greater than ± 0.8 between at least one immune cell subtype and all others. See Zheng et al. 17 for further justification and validation.
The CellDMC algorithm. CellDMC consists of three basic steps: (1) estimation of cell-type fractions in a given sample using EpiDISH 16 or HEpiDISH 17 , depending on the cell-type resolution desired (as described in previous section), (2) estimation of DMCTs for a given phenotype of interest (binary or continuous) and (3) ranking of DMCTs per cell type.
The key idea behind CellDMC is that a DNAm alteration occurring in a specific cell type will exhibit a significant interaction between the phenotype and the corresponding cell-type fraction variable. To introduce relevant notation, we shall assume that we have a DNA methylation beta-valued (β ) matrix x cs , with c(c = 1,..,C) labeling the CpGs and s(s = 1,… ,S) labeling the samples. For each sample s, let y s denote the phenotype (for example, a 0 or 1 variable for binary phenotypes, or a continuously valued number for continuous phenotypes), and let ( ) are regression coefficients to be estimated and * denotes the interaction term, and where we assume that errors are Gaussianly distributed with a variance that may depend on the specific CpG c. We note that the above summations don't run over all K cell types, because cell-type fractions are normalized and must add up to 1. Because of this normalization constraint, the intercept term and the phenotype main effects term can be absorbed into the corresponding summations, so that an equivalent model is
The regression coefficients β ck I ( ) inform us as to whether there is a significant interaction between the phenotype and the corresponding fraction for cell-type k. We note that if differential methylation associated with the phenotype occurs at a CpG c and in cell-type k, the observed differential methylation should be larger in samples with high fractions for that cell-type k compared to samples with low content for cell-type k, and should be detectable via a statistically significant interaction term β ck I ( ) . We solve the above model using leastsquares with the lm function in R, which provides estimates for the regression coefficients and their statistical significance via P values P ck I ( ) . The P values P ck I ( ) for each cell-type k are adjusted for multiple hypothesis testing using BenjaminiHochberg (BH) FDR estimation. For those CpGs with BH-FDR values less than a predefined significance threshold (typically BH-FDR < 0.05), we call it a DMCT in the given cell type. Finally, CpGs can be ranked within each cell type according to the associated P value of significance.
Finally, we note that additional covariates representing other biological factors (for example, age, gender or ethnicity) or technical factors (batch) can be included in the above model. For instance, for a set Q of such factors, let ⇀ z q (q = 1…Q) denote the factor values across the S samples, and then the model above becomes
DNA methylation data sets used for in silico mixture simulation experiments.
The following lists the DNAm data sets used in this manuscript to generate the in silico mixtures, with their Gene Expression Omnibus (GEO, https://www. ncbi.nlm.nih.gov/geo) accession numbers or download links. We note that none of these samples was used in the construction of the DNAm references used in EpiDISH and HEpiDISH and the samples are therefore truly independent: Illumina 450k data of four epithelial cell lines and ten fibroblast cell lines from Stem-Cell Matrix Compendium-2 (SCM2) 36 (GSE31848); Illumina 450k data of eight B cells, 71 CD4
+ T cells and 28 monocytes from Absher et al. 37 (GSE59250); Illumina 450k data of 31 CD4 + T cells from Limbach et al. 38 (GSE71955); Illumina 450k data of four B cells, six CD4
+ T cells and five monocytes from Mamrut et al. (GSE71244); Illumina 450k data of 36 monocytes from Marabita et al. 39 (GSE43976); Illumina 450k data of eight CD4 + T cells from Nestor et al. 40 (GSE50222); Illumina 450k data of 214 CD4 + T cells and 1,202 monocytes from Reynolds et al. 41 (GSE56047); and Illumina 450k data of six B cells, six CD4 + T cells and six monocytes from Zilbauer et al. 42 (https://www.ebi.ac.uk/ arrayexpress/experiments/E-MTAB-2145/). Two fibroblast cell lines were removed from SCM2 data set after purity check. All of the above Illumina 450k data together comprised the purified cells pool for generating in silico mixtures. In total, we have four epithelial cell lines, eight fibroblast lines, 66 B cells, 336 CD4
+ T cells and 1,277 monocytes. We also downloaded processed WGBS bed files from IHEC (http:// epigenomesportal.ca/ihec), samples that we expected to be of relatively high purity, representing epithelial, fibroblast and immune cell subtypes. Samples of low WGBS coverage or sequencing depth were removed. A total of six epithelial cells (four podocytes and two breast epithelial), two fibroblast or stromal cells, eight B cells, 11 CD4
+ T cells and nine monocyte samples were included. After merging them together, the number of common CpGs was 220,351. Only 381 of the 716 cell-type CpGs in EpiFibIC reference could be found. Thus, purity estimates were checked using 381 CpGs in the EpiFibIC reference using EpiDISH. One podocyte sample was predicted to have a high fibroblast fraction and was removed. For the in silico mixtures, we thus used five epithelial, two fibroblast, eight B cells, 11 CD4
+ T cells and nine monocyte WGBS samples.
Generation of in silico mixtures.
To test performance of CellDMC in terms of sensitivity and specificity, we generated 200 in silico mixtures with half representing controls and the other half representing cases (disease). For cases, we altered the DNAm levels of 150 CpGs in specific cell types, thus defining true DMCTs (and DMCs). For each of the 200 mixtures, we randomly sampled an epithelial cell, fibroblast, B cell, CD4 + T cell and monocyte from the corresponding pools of purified cells, and mixed them together with five weights drawn from a Dirichlet distribution. Because for each sample, DNAm changes were made to all immune cells (B cells, CD4
+ T cells and monocytes)
simultaneously and equally, we could treat this as a three cell-type mixture (epithelial cells, fibroblasts and immune cells) problem, in which we inferred the total immune cell fraction alongside the total epithelial and fibroblast fractions. We considered five different DMCT scenarios, including unidirectional DNAm changes in all three cell types, unidirectional changes in two cell types, unidirectional changes in one cell type, bidirectional changes in three cell types and bidirectional changes in two cell types. For each scenario, we also had five different SNRs with values of 3, 2.4, 1.8, 1.2 and 0.9, corresponding to approximate absolute DNAm differences in individual cell types (between cases and controls) of 0.42, 0.32, 0.22, 0.12 and 0.12, respectively. The latter two SNR values differ because we increased the variance in the case where SNR = 0.9. For every scenario, we ran 100 Monte-Carlo runs. We also considered scenarios in which a DNAm change was induced in only a particular immune cell subtype (and not in all immune cells simultaneously), in which case we used HEpiDISH to estimate the cell-type fractions for all immune cell subtypes, in addition to the total epithelial and fibroblast fractions. We also considered a scenario mimicking a blood EWAS, in which we mixed together only purified immune cell subtypes.
The overall strategy used to generate in silico mixtures with a continuous phenotype is similar to that used for a binary phenotype. For each sample, the continuous phenotype y was assumed to take a value between 0 and 1. In the case where y = 1, the corresponding β was sampled as described previously for disease samples in the binary phenotype context, whereas for samples with values y < 1, the altered β -values were correspondingly scaled by y. The SNR values were defined at y = 1.
In the scenario in which we allow for a bimodal distribution within the disease phenotype, we use the same parameters as for the binary phenotype case. The only difference is that for each DMCT, only 70% of the disease samples were randomly selected to be altered, whereas the other 30% disease samples were modeled as control or normal samples.
Perturbations of cell-type fraction point estimates. We used two different approaches to assess the robustness of CellDMC to the use of cell-type fraction point estimates. Briefly, in one approach, instead of using the point estimates, we randomly sampled a number from the interval given by point estimate ± 3σ . In the second approach, we bootstrapped DMCs that made up the reference matrix, thus generating a new reference DNAm matrix with the same number of DMCs but with several of these appearing multiple times. Inference of cell-type fractions was then performed using this bootstrapped DNAm reference matrix, with the new point estimates subsequently used in CellDMC.
Simulations involving missing cell types in DNAm reference matrix. To study the impact of missing cell types, we first considered a scenario in which there are three cell types with one cell type differentially methylated (Uni-1C scenario) and another cell type missing. We altered only epithelial cells, introducing 150 true epithelial DMCTs. Cell-type fractions were then estimated using the EpiFibIC reference matrix but with one cell type (fibroblasts) missing from the reference DNAm matrix. Correspondingly, CellDMC was subsequently run with only two cell types. When we generated the in silico mixtures, the cell-type fractions for all three cell types were drawn from a uniform Dirichlet distribution, so that each cell type exhibited the same underlying mean and variance for the fraction.
We also ran a second simulation with two of the three cell types altered (Uni-2C scenario), and with one of the altered cell types missing from the DNAm reference.
In a third analysis, we focused on blood tissue, considering the Uni-1C scenario. We generated in silico mixtures of five blood cell subtypes (B cells, CD4
+ and CD8 + T cells, monocytes and neutrophils) using the pools of purified blood cell subtypes we constructed earlier, drawing cell proportions from a weighted Dirichlet distribution, with weights determined to yield realistic celltype fractions in blood, as inferred from a blood EWAS 5 . As before, 150 DMCTs were generated within one cell type only (we chose CD4 + T cells) with sensitivity and specificity computed by CellDMC using a DNAm reference matrix that did not include another cell type (we chose CD8 + T cells). As in all other simulations, a total of 100 Monte-Carlo runs were performed, with each run simulating 100 cases and 100 controls. We benchmarked results against the scenario in which none of the five cell subtypes was missing from the DNAm reference matrix.
Implementation of CellDMC on in silico mixtures and definition of sensitivity and specificity. We estimated cell-type fractions of all in silico mixtures using EpiDISH (RPC mode) with a reference 17 , which consists of 716 cell type-specific DMCs, to estimate fractions of three major cell types (generic epithelial cells, generic fibroblasts and total immune cells). Next, CellDMC was run with the estimated fractions, multiple hypothesis correction method set to "FDR," and FDR (adjusted P value) threshold of 0.05, which resulted in a matrix containing predicted DMCT(s) and a matrix of coefficients for each cell type including predicted DNAm change and raw and adjusted P values, ranked by selected cell type. As long as a CpG in one cell type was predicted to be a DMCT, it was counted as a predicted DMC. Detection sensitivity for DMCs was defined as the number of predicted true DMCs divided by 150 (true number of DMCs). Detection sensitivity for DMCT was defined as the mean sensitivity for correctly predicting DMCTs (considering directionality of change) averaged over all relevant cell types. In the case in which we induced DNAm changes in individual immune cell subtypes, we estimated cell-type fractions for all cell types using our HEpiDISH framework, but all subsequent analysis proceeded as for the threecell-type scenario above.
Power calculations.
To estimate the appropriate sample size to achieve a certain sensitivity and specificity, we performed corresponding power calculations for a DNAm change in one cell type (Uni-1C) and unidirectional changes in all cell types (Uni-AllC) scenarios. For each scenario, we did 100 Monte-Carlo runs for five SNR(s) as described earlier. We varied sample sizes from 10 to 500 (including 10, 20, 30, 40, 50, 100, 150, 200 , 300 and 500) in each case with half of these as controls and the other half as cases. Mean sensitivities for DMCT detection over 100 Monte-Carlo runs were calculated.
Simulation analysis of cell-type complexity. For K = 3, we mixed epithelial, fibroblast and monocytes and used EpiDISH with EpiFibIC DNAm reference to estimate cell-type fractions. For larger K values, we iteratively added one more immune cell subtype to the mix in the order of neutrophils (K = 4), CD4 Application of CellDMC to a blood rheumatoid arthritis EWAS to detect B cell-specific rheumatoid arthritis DMCs. We obtained Illumina 450k data profiling peripheral blood for 335 controls and 354 rheumatoid arthritis cases from Liu et al. (GSE42861) 5 . Data were normalized as described 29 . We estimated cell-type fractions of all seven major immune cell subtypes (B cells, CD4
+ T cells, CD8 + T cells, natural killer (NK) cells, monocytes, neutrophils and eosinophils) using EpiDISH with a DNAm reference consisting of 333 immune cell type-specific DMCs 16 . All parameters of CellDMC were the default choices. We tested CellDMC's predictions against ten B cell-specific rheumatoid arthritis CpGs, which had been validated in three independent purified B-cell EWAS data sets, as reported in Julià et al. 24 . To assess the statistical significance of CellDMC's DMCT predictions, we randomly picked ten CpGs 100,000 times, and compared the weighted t-statistics of the estimated B cell-specific regression coefficients to the observed ones. P values were calculated as the number of runs in which the t-statistic was larger than the original observed one, divided by the number of runs.
Application of CellDMC to endometrial cancer. We downloaded and processed level 3 Illumina 450k data of uterine corpus endometrial carcinoma from TCGA 28 . This data set contains 374 cancer samples and 34 normal adjacent control samples. We estimated cell-type fractions for the total epithelial, total fibroblast and total immune cell components, using our previously validated EpiFibIC DNAm reference (716 cell type-specific DMCs).
Application of CellDMC to a breast cancer EWAS.
To test CellDMC's ability to detect DMCTs occurring in breast cancer epithelial cells, we used a breast cancer tissue DNAm 450k data set, which included 92 normal controls and 305 breast cancer cases, from Teschendorff et al. (GSE69914) 18 . We estimated celltype fractions using EpiDISH in conjunction with a previously validated DNAm reference for breast tissue, consisting of 491 cell type-specific DMCs and four cell types (generic epithelial, generic fibroblast, fat and total immune cell) 17 . All parameters choices in CellDMC were the default ones. The true positive breast cancer epithelial DMCTs or DMCs and a corresponding list of true negatives were constructed as reported in Zheng et al. 9, 17 .
Application of CellDMC to a buccal smoking EWAS and validation in lung squamous cell carcinoma. The smoking buccal Illumina 450k data set was processed as described in Teschendorff et al. 30 . Using EpiDISH and EpiFibIC DNAm reference, we estimated cell-type fractions of total epithelial cells, total fibroblasts and total immune cells. Because the estimated fractions of fibroblasts in all samples were quite small with mean < 0.05, we included only epithelial cells and immune cells when running CellDMC, which was run with smoking pack years as the phenotype. Among all 790 samples in the data set, we used only 647 samples for which smoking pack year information was available.
DMCTs predicted to occur specifically in the epithelial compartment of buccal swabs were validated in the Illumina 450k lung squamous cell carcinoma (LSCC) data, generated as part of TCGA 32 . We only only DMCTs with similar DNAm levels in epithelial and blood cell subtypes in samples not exposed to smoking, as only for these would we expect to see an association between their DNAm levels and the estimated epithelial fraction in the tumors. To this end, we collected Illumina 450k data of 11 different epithelial cell lines (Hipe, Saec, Hre, Hae, Hrpe, Prec, Hee, Hcpe, Hnpce, Hmec and Hrce) from ENCODE (GSE40699) and a total of 42 purified samples representing all seven major immune cell types (neutrophils, eosinophils, monocytes, CD4
+ and CD8 + T cells, B cells and NK cells) from Reinius et al. 43 (GSE35069) to identify CpGs with the same ground state of DNAm level in epithelial and immune cells. We used limma (an empirical Bayes framework) 44 to select 277,801 CpGs with P > 0. 5 
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Data collection
All data analyzed in this manuscript is already publicly available from GEO (www.ncbi.nlm.nih.gov/geo/) or from the TCGA data portal (https://gdc.cancer.gov). No software was used to collect data.
Data analysis
The purpose of our study was to present a new software tool, CellDMC, which is freely available as a user-friendly R-script within the EpiDISH Bioconductor package, freely available from github (https://github.com/sjczheng/EpiDISH), and in due course also from Bioconductor (https://www.bioconductor.org).
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Sample size
In the case of the applications to real data, sample sizes were already predetermined since alll datasets have already been published. In the case of simulation, we have included a detailed power analysis in Fig.2c and Suppl. Fig.7 for a range of sample sizes that are relevant to current and future EWAS.
Data exclusions Two fibroblast cell lines DNAm profiles have been excluded from in-silico mixtures due to low purities as described in Suppl.Data.1. This was pre-established from our previous publication published in Epigenomics (see Zheng SC et al Epigenomics 2018), where we had already observed low purity for a few specific "fibroblast" cell-lines.
Replication
In the case of simulations, we always ran 100 Monte Carlo runs to ensure reproducibility of findings. In the case of the real data applications, we tested reproducibility and robustness to choice of cell-type fraction estimation algorithm or to missing cell-types. In all cases, we have found results to be well reproducible.
Randomization This is only relevant to the applications on real data. We note that the real datasets analysed here are publicly available and were already generated as part of other studies. We further note that the 3 real datasets analysed here (the whole blood RA study from Liu et al, our own buccal swab smoking EWAS and the TCGA LSCC dataset) have all already been analysed by us in previous publications (Yuan T et al PLoS Genetics 2015, Teschendorff AE et al JAMA Oncology 2015 and Chen Y et al Genome Biol.2017) where we have noted that these particular studies are not subject to substantial confounding by technical factors. Hence there was no need to include technical covariates in our analyses. The only covariates included were those capturing cell-type heterogeneity effects, which is the dominant source of DNAm variation in these datasets.
Blinding
This is not applicable here since we are not analyzing an unpublished novel dataset. Where we perform validation of detected DMCTs on real datasets, the validation is always performed on datasets not used in the discovery of DMCTs, as required.
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